← Browse by Condition
Medical Condition
diffuse large b cell lymphoma
Total Trials
21
Recruiting Now
21
Trial Phases
Phase 2, Phase 1, Phase 2, Phase 1
NCT05281809 Phase 2
Recruiting
Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia
Enrollment
30 pts
Location
United States
Sponsor
John Lister
NCT05006716 Phase 1, Phase 2
Recruiting
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
Enrollment
614 pts
Location
United States, Austr...
Sponsor
BeOne Medicines
NCT04739813 Phase 1
Recruiting
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma
Enrollment
55 pts
Location
United States
Sponsor
National Cancer Institute (NCI...
NCT06625203
Recruiting
A Non-interventional, International, Multicentre Clinical Research Study to Build the Largest Collection of Multimodal Data (Including Clinical Data, Imaging Data and Omics Data) in Oncology
Enrollment
7,000 pts
Location
United States, Franc...
Sponsor
OWKIN
NCT05255354
Recruiting
Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing CAR Therapy
Enrollment
300 pts
Location
United States
Sponsor
Adaptive Biotechnologies
NCT05952024 Phase 2
Recruiting
Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL
Enrollment
80 pts
Location
United States, Brazi...
Sponsor
AstraZeneca
NCT06530511 Phase 2
Recruiting
Polatuzumab, Rituximab and Orelabrutinib Combination Regimen (PRO) in the Treatment of Elderly Frail Patients with Treatment-naive Non-GCB DLBCL
Enrollment
30 pts
Location
China
Sponsor
Affiliated Hospital of Nantong...
NCT06131801
Recruiting
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Enrollment
30 pts
Location
United States
Sponsor
Children's Hospital Medical Ce...
NCT04670029 Phase 3
Recruiting
Impact of an APA Program on EFS in Patients With Diffuse Large-cell B Lymphoma Treated in 1st Line
Enrollment
186 pts
Location
France
Sponsor
Weprom
NCT01804686 Phase 3
Recruiting
A Long-term Extension Study of PCI-32765 (Ibrutinib)
Enrollment
700 pts
Location
United States, Argen...
Sponsor
Janssen Research & Development...
NCT06830759
Recruiting
Real-World Study to Assess Subcutaneous Epcoritamab in Adult Participants With Diffuse Large B-Cell and Follicular Lymphoma
Enrollment
700 pts
Location
Argentina, Australia...
Sponsor
AbbVie
NCT04300101
Recruiting
Mixed Molecular Clinical Index (MMCI) in Diffuse Large B-cell Lymphoma (DLBCL)
Enrollment
300 pts
Location
Italy
Sponsor
Istituto Romagnolo per lo Stud...
NCT06760039 Phase 1, Phase 2
Recruiting
Safety and Efficacy of R-CMOP Versus R-CHOP in the Initial Treatment of DLBCL
Enrollment
112 pts
Location
China
Sponsor
Sun Yat-sen University
NCT05351346 Phase 3
Recruiting
Genotype-guided Treatment in DLBCL
Enrollment
1,100 pts
Location
China
Sponsor
Ruijin Hospital
NCT02393157 Phase 2
Recruiting
Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL
Enrollment
25 pts
Location
United States
Sponsor
New York Medical College
NCT06898905
Recruiting
Hyperfractionated Dual Equivalent Fractionated Radiation Therapy
Enrollment
10 pts
Location
United States
Sponsor
Yale University
NCT02227251 Phase 2
Recruiting
Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Enrollment
244 pts
Location
United States, Austr...
Sponsor
Karyopharm Therapeutics Inc
NCT06517004 Phase 1
Recruiting
An Open-label, Single-arm Study of JWCAR201 in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
Enrollment
9 pts
Location
China
Sponsor
Fudan University
NCT05432635 Phase 1
Recruiting
Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma
Enrollment
15 pts
Location
United States
Sponsor
City of Hope Medical Center
NCT05139017 Phase 2, Phase 3
Recruiting
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
Enrollment
290 pts
Location
United States, Argen...
Sponsor
Merck Sharp & Dohme LLC
NCT06244368 Phase 2
Recruiting
GVM±R in Patients With Relapsed or Refractory Aggressive NHL.
Enrollment
115 pts
Location
China
Sponsor
Institute of Hematology & Bloo...